New hope for Tough-to-Treat lymphoma: experimental combo aims to shrink tumors fast

NCT ID NCT05364424

Summary

This study tested a new combination of drugs for people with an aggressive type of lymphoma (DLBCL) that had come back or stopped responding to their first treatment. The goal was to see if adding a new drug called glofitamab to a standard chemotherapy regimen could effectively shrink tumors and control the disease, making patients eligible for a follow-up stem cell transplant or CAR-T therapy. Researchers measured how well and safely the combination worked in 43 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chao Family Comprehensive Cancer Center UCI

    Orange, California, 92868, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Memorial Cancer Institute at Memorial West

    Pembroke Pines, Florida, 33028, United States

  • New York University Langone Medical Center

    New York, New York, 10016, United States

  • The University of Chicago

    Chicago, Illinois, 60637, United States

  • Tulane Medical Center

    New Orleans, Louisiana, 70112, United States

  • UMASS Memorial Medical Center

    Worcester, Massachusetts, 01655, United States

Conditions

Explore the condition pages connected to this study.